

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/233872 A1

(51) International Patent Classification:

C07D 498/10 (2006.01) C07D 515/10 (2006.01)
C07D 471/10 (2006.01) A61K 31/438 (2006.01)
C07D 513/10 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/EP2022/061851

(22) International Filing Date:

03 May 2022 (03.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/183,321 03 May 2021 (03.05.2021) US

(71) Applicant: **JAZZ PHARMACEUTICALS IRELAND LIMITED** [IE/IE]; Waterloo Exchange, Waterloo Road, Dublin, 4 (IE).

(72) Inventor; and

(71) Applicant: **MARINELLI, Davide** [IT/IT]; c/o Jazz Pharmaceuticals Ireland Limited, Waterloo Exchange, Waterloo Road, Dublin, 4 (IE).

(72) Inventors: **CHOVATIA, Praful**; c/o Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB). **BEATO, Claudia**; c/o Aptuit (Verona) SRL, Via A. Fleming 4, 37135 Verona (IT). **OUVRY, Gilles**; c/o Evotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB).

(74) Agent: **COOLEY (UK) LLP**; 22 Bishopsgate, London Greater London EC2N 4BQ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: OREXIN RECEPTOR AGONISTS AND USES THEREOF



(1)

(57) Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein n, m, A₁, A₂, A₃, A₄, A₅, A₆, L₁, L₂, R₁, R₂, R₃, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a disease or disorder that is treatable by administration of an Orexin agonist.



WO 2022/233872 A1